14 completed, 6 unknown, 4 active not recruiting, 4 recruiting. 32 Phase 2, 5 Phase 3, 4 Phase 1.
Follow Positron Emission Tomography Computed Tomography: new trials by email Literature Review of Positron Emission Tomography Computed Tomography trials Research Report on Positron Emission Tomography Computed Tomography
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Colon Cancer Diagnosis With FAPI-PET Imaging PET/CT ([F-18]FAPI-74) - Colon Cancer | Phase 2 / Phase 3 | Recruiting | Turku University Hospital | 100 | 2024-10-09 | 2025-12-09 |
| Pancreatic Cancer Diagnosis With FAPI-PET Imaging PET/CT - Positron Emission Tomography, Pancreatic Cancer | Phase 2 / Phase 3 | Recruiting | Turku University Hospital | 100 | 2024-10-09 | 2025-08-01 |
| Biomarkers to Detect Endocrine Therapy Resistance 18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography - Metastatic Cancer, Breast Cancer | Phase 2 | Recruiting | University of Wisconsin, Madison | 8 | 2024-04-30 | 2026-08-25 |
| Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer Metformin, Radiotherapy, Chemotherapy - Cervical Cancer, Radiotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 51 | 2024-04-15 | 2025-01-14 |
| A Study of Imaging in Demyelinating Diseases C-11 ER176 Radiotracer, C11 Pittsburgh Compound B, PET/CT scan - Multiple Sclerosis, Inflammatory Demyelinating Disease | Phase 2 | Enrolling by invitation | Mayo Clinic | 200 | 2023-07-10 | 2026-09-17 |
| Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors Al18F-NOTA-octreotide, PET/CT, PET/MR - Neuroendocrine Tumors | Phase 2 / Phase 3 | Completed | Universitaire Ziekenhuizen KU Leuven | 85 | 2020-10-07 | 2022-02-17 |
| PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy PET/CT, radioactive drug (tracer) - Cancer | Phase 1 / Phase 2 | Completed | Mayo Clinic | 6 | 2020-08-14 | 2023-09-13 |
| A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma 89Zr-DFO-daratumumab, PET/CT - Multiple Myeloma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-06-30 | 2022-07-01 | |
| Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment [18-F]- FDG - PET, Tumor ablation (TA), PET/CT Scan - Liver Metastases | Phase 2 / Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 200 | 2019-10-25 | 2026-11-03 |
| ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy High dose chemotherapy before allogeneic stem cell transplantation (alloSCT), Bone marrow histology, clinical and laboratory parameters - Aggressive Non-hodgkin Lymphoma (aNHL), Lymphoma, B-Cell | Phase 2 | Completed | GWT-TUD GmbH | 60 | 2019-06-24 | 2023-05-24 |
| 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392 - Cigarette Smoker, Current Smoker | Phase 2 | Completed | Andrei Iagaru | 15 | 2019-02-04 | 2025-04-09 |
| PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Paclitaxel, Cisplatin, Oxaliplatin - Neoplasm, Esophageal, Squamous Cell Carcinoma | Phase 2 | Unknown | Mian XI | 216 | 2019-01-15 | 2021-03-23 |
| First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody 89Zr-daratumumab, PET/CT scans, Blood draws - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 11 | 2018-09-05 | 2021-07-30 |
| Imaging With a PET Agent for Detection of Cancers of the Head and Neck [18F]- PARPi, PET/CT Scans - Head and Neck Cancer | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2018-08-10 | 2026-09-08 |
| Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. Carfilzomib, Lenalidomide, PET-CT - Myeloma | Phase 2 | Active not recruiting | Oslo University Hospital | 53 | 2018-03-16 | 2025-08-08 |
| A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms 18F-AlF-NOTA-octreotide, PET/CT - Neuroendocrine Neoplasm | Phase 1 / Phase 2 | Unknown | Xiangya Hospital of Central South University | 65 | 2018-01-02 | 2018-04-30 |
| PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2, PET/CT - Neuroendocrine Tumors | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 113 | 2017-12-04 | 2022-06-30 |
| The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD Bendamustine, Gemcitabine, Dexamethasone - Hodgkin's Lymphoma | Phase 2 | Completed | Polish Lymphoma Research Group | 115 | 2017-11-06 | 2025-01-16 |
| PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 One injection of 68Ga-NOTA-AE105, PET/CT - Neuroendocrine Tumors | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 116 | 2017-11-01 | 2022-06-30 |
| PSMA PET Imaging of Recurrent Prostate Cancer Ga-HBED-iPSMA PET, PET/CT, MRI - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 1171 | 2017-06-26 | 2026-08-26 |
Showing 20 of 32. Sign in to see all of them.
Neuroendocrine Tumors (4) · Prostatic Neoplasms (4) · Breast Neoplasms (2) · Hodgkin Disease (2) · Leukemia (2) · Lymphoma (2) · Multiple Myeloma (2) · Adenocarcinoma (1) · Carcinoma, Lobular (1) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1) · Disease (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1)
Memorial Sloan Kettering Cancer Center (7) · Copenhagen University Hospital, Rigshospitalet (4) · Turku University Hospital (3) · Mayo Clinic (2) · Andrei Iagaru (1) · ECOG-ACRIN Cancer Research Group (1) · GWT-TUD GmbH (1) · Mian XI (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute (NCI) (1) · Oslo University Hospital (1) · Peking Union Medical College Hospital (1) · Polish Lymphoma Research Group (1) · Stanford University (1) · Thomas Hope (1)
United States (14) · Denmark (5) · China (4) · Finland (3) · Belgium (1) · Brazil (1) · Germany (1) · Norway (1) · Poland (1) · Sweden (1)
Esben Carlsen, MD (2) · Andrei Iagaru (1) · Angelita Habr-Gama, MD, PhD (1) · Bertram Glass, Prof. Dr. (1) · Burcu Zeydan, MD (1) · Carina Mari Aparici (1) · Carlos A Buchpiguel, MD, PhD (1) · Christophe Deroose, MD, PhD (1) · Constantinos Sofocleous, MD, PhD (1) · Dorthe Skovgaard, MD PhD (1) · Gary Ulaner, MD, PhD (1) · Heikki Minn, Professor (1) · Herbert Vargas Alvarez, MD, PhD (1)
PMID 20150268, PMID 22086847, PMID 22580120, PMID 24509716, PMID 26911200, PMID 27152857, PMID 28522741, PMID 29147764, PMID 31039025, PMID 33054114, PMID 34529005, PMID 36265911, PMID 37261615, PMID 37482512, PMID 38837825, PMID 39638553, PMID 41874299
2017 (2), 2016 (1), U01CA079778 (1), U01CA080098 (1)